Inogen, Inc. INGN is well-poised for growth in the coming quarters, backed by high prospects in the portable oxygen concentrator (POC) space. The optimism, led by a diversified and expanding product portfolio, strong momentum in international markets and a growing total addressable market, seems justified. However, U.S. revenue pressure from channel shifts and macroeconomic conditions remains a key risk.
This Zacks Rank #3 (Hold) company’s shares have gained 3.6% in the year-to-date period against the industry’s 12.7% decline. The S&P 500 has risen 3.3% during the same timeframe.
The renowned provider of POCs has a market capitalization of $189.26 million. The company projects 16.3% earnings growth for 2026 and anticipates continued business improvements going forward. Inogen’s P/S ratio of 0.5 compared with the industry’s 3.05 makes its valuation attractive.
Image Source: Zacks Investment Research
Let’s delve deeper.
Factors Driving INGN’s Prospects
Demand for POCs & Market Shift: Inogen is benefiting from a structural shift in the long-term oxygen therapy (LTOT) market toward portable oxygen concentrators (POCs). Its lightweight, battery-powered systems, such as the Inogen One and Inogen Rove, enable greater mobility and convenience compared to traditional stationary concentrators and oxygen tanks. Adoption is accelerating, with about 59% of new LTOT patients starting on POCs and unit volumes growing over 20% year over year in 2025.
Diversified Product Portfolio & Expanding TAM: Inogen’s expanding product lineup positions it well for future growth.The company has expanded beyond POCs into airway clearance (Simeox), stationary oxygen (Voxi 5) and sleep therapy (Aurora CPAP masks). These additions increase its TAM from $400 million to over $3 billion. Early traction is encouraging, with Simeox generating over $6 million in 2025 revenues and Voxi 5 showing strong initial uptake. The upcoming CPAP mask launch targets a $2.2 billion market, with significant cross-selling potential.
International Expansion: International markets emerged as a clear bright spot, with fourth-quarter 2025 revenues growing 15% year over year to $32.5 million. Growth was driven by stronger demand, deeper relationships with home medical equipment (HME) providers and success in securing key tenders. Management emphasized that global COPD markets remain underpenetrated, with long-term oxygen therapy still underutilized in many regions. This creates a multi-year runway for expansion.
INGN: Key Risks to Watch
U.S. Revenue Pressure & Channel Mix Shift: Fourth-quarter 2025 U.S. sales declined 5.1% year over year, reflecting both delayed customer orders and a broader shift toward B2B channels. While B2B growth supports volume expansion, it creates headwinds for higher-margin direct-to-consumer (DTC) and rental segments. This evolving channel mix is expected to continue pressuring near-term revenue visibility and margins.
Macroeconomic Concerns: Inogen faces macroeconomic risks that could pressure demand and operations. Factors such as inflation, interest rate changes, geopolitical instability and weaker consumer spending may lead customers, distributors and healthcare providers to delay or reduce purchases of respiratory equipment. Global supply chain constraints around raw materials and semiconductor components used in portable oxygen concentrators can raise procurement costs and create sourcing challenges. These pressures may increase the cost of sales, compress margins and limit the company’s ability to meet demand efficiently.
Inogen, Inc Price
Inogen, Inc price | Inogen, Inc Quote
INGN’s Estimate Trend
Inogen has been witnessing a negative estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for its loss per share has expanded by 21 cents to 72 cents.
The Zacks Consensus Estimate for 2026 revenues is pegged at $369.2 million, suggesting a 5.9% improvement from the year-ago reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Globus Medical GMED, Phibro Animal Health PAHC and Cardinal Health CAH. While GMED sports a Zacks Rank #1 (Strong Buy) at present, PAHC and CAH carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of GMED have gained 7.4% in the year-to-date period. Estimates for the company’s 2026 earnings per share (EPS) have increased by 1 cent to $4.46 in the past 30 days. GMED’s earnings surpassed estimates in three of the trailing four quarters and missed one, the average surprise being 18.8%. In the last reported quarter, it delivered an earnings surprise of 20.8%.
PAHC shares climbed 44.8% in the year-to-date period. Estimates for the company’s 2026 EPS have remained constant at $3.03 in the past 30 days. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.1%. In the last reported quarter, it delivered an earnings surprise of 26.1%.
CAH shares lost 0.3% in the year-to-date period. Estimates for the company’s 2026 EPS have increased by 1 cent to $10.32 in the past 30 days. CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 9.3%. In the last reported quarter, it posted an earnings surprise of 10%.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report
Inogen, Inc (INGN): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).